Testimonials

Since Tri-Solfen^® was commercially launched, over 150 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Country	Species	Patent
Australia	Sheep	Granted
Australia	Horses, Dogs, Lab animals	Granted
Australia	Cattle	Granted
Australia	Humans	Granted
New Zealand	Sheep, Cattle	Granted
New Zealand	Horses, Dogs, Lab animals	Granted
EU	Humans	Granted
EU	Pig, Sheep, Cattle	Granted
USA	Dogs, Horses, Lab animals	Granted
USA	Humans	Granted
USA	Pig, Sheep, Cattle	Granted
Canada	Horses, Dogs, Lab animals	Granted
Canada	Cattle, Pig	Granted
Canada	Humans	Granted

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Press Release

Australian beef and dairy industry welcomes new registrations for Tri-Solfen^®

July 9, 2018

Patented pain relief product for animal husbandry procedures is marketed by Bayer in Australia

Expands Tri-Solfen’s^® commercial potential

Dossier submitted to the EMA for registration of Tri-Solfen^® in Europe

Melbourne, Australia – 9 July 2018 – Medical Ethics Pty Ltd (“Medical Ethics” or “the Group”), a commercial research and development company focused on pain mitigation in wounds for humans and animals, announces that its wholly owned subsidiary, Animal Ethics Pty Ltd (Animal Ethics), has successfully received approval from the Australian Pesticides and Veterinary Medicines Authority (APVMA) to extend the use of Tri-Solfen® in Australia to include pain relief for beef and dairy calves.

Anthony (Bim) Struss, President of AgForce Cattle Board, Councillor of the Cattle Council Australia and Member of the Queensland Animal Welfare Advisory Board, commented:
“We have seen widespread use of Tri-Solfen^® across the beef cattle industry since the initial registration of the product in cattle in 2014 and we welcome this extended use. Farmers are increasingly seeking a way to improve welfare standards and Tri-Solfen^® provides a safe and effective way to reduce pain and improve wound healing more broadly across livestock.”

Kathryn Davis, Program Leader, Animal Health & Fertility at Dairy Australia, commented:
“This is great news for dairy calf welfare. It is now easy for farmers to provide cheap and effective pain relief on site for calves following husbandry procedures.”

Tri-Solfen® is an innovative spray and stay topical local anaesthetic and antiseptic gel that is designed to adhere to wounds to provide rapid onset numbing with prolonged analgesia effects. It also contains active ingredients designed to minimise bleeding, protect against infection, coat the wound and promote healing.

Tri-Solfen® was approved in lambs in 2004, becoming the first topical local anaesthetic pain relief product specifically developed and approved for on-farm use to address husbandry-related pain in infant livestock. Since then, the product has been approved for use in beef calves, and has been widely adopted by Australian farmers in what has become a revolution in farm animal welfare, with over eight million lambs and one million calves treated with the pain relief product each year.

With over one billion livestock animals globally undergoing highly invasive painful husbandry procedures annually, and a critical shortage of products available for on-farm pain alleviation, Animal Ethics is continuing its drive to deliver solutions by pursuing extensions of use for different species, for an increasing range of wound applications, as well as expanding to international markets. The process for securing a European registration for Tri-Solfen® through the Group’s partner, Dechra Veterinary Products, an international specialist veterinary pharmaceutical company, began last month with a dossier being submitted to the European Medicines Agency for painful husbandry procedures in piglets and dairy calves to be treated with the proven technology.

Tri-Solfen® is already registered in Australia separately for pain alleviation in sheep and cattle husbandry procedures, where it is marketed and distributed by Bayer Animal Health, a global leader in animal health. To date, Tri-Solfen® has been used to successfully treat over 80 million animals undergoing routine surgeries in the Australian livestock industries.

Allan Giffard, Managing Director of Medical Ethics, added:
“Animal Ethics is proud to be part of the global movement to address animal pain. Not only does Tri-Solfen® deliver improved welfare, but farmers report, that they also notice the big impact on productivity. Tri-Solfen® is proven to deliver a highly effective, practical and cost-efficient solution to improve animal welfare outcomes. This label extension is another important step for Medical Ethics as we continue to build the value of the brand by expanding the indications for which our products are used and our international reach. We are continuing to make good progress towards the registration of Tri-Solfen® in Europe with our partner, Dechra Veterinary Products. We are also committed to investing for long term sustainable growth and further develop our recognised technology in humans. I look forward to providing an update on this in due course.”

– Ends –

Contacts:
Medical Ethics Pty Ltd
Allan Giffard, Managing Director
Charles Olsson, Marketing Director
Tel: +61 419 362 286

FTI Consulting
Brett Pollard / Victoria Foster Mitchell
Tel: +44 20 3727 1000

Notes for editors:
About Medical Ethics Pty Ltd
Medical Ethics Pty Ltd is a commercial research and development company focused on pain mitigation in wounds for humans and animals. Our vision is to develop and deliver our highly effective, safe, affordable and practical pain relief products to prevent pain and minimise suffering associated with wounds in humans, livestock and companion animals. Medical Ethics is focused on the development of the Group’s patented technology initially for the treatment of chronic wounds such as diabetic leg ulcers. Animal Ethics, a wholly owned subsidiary of Medical Ethics, is the first, and currently the only, company globally to develop, launch and commercialise a topical pain and wound management product for use in livestock undergoing painful husbandry procedures.

In March 2017, Medical Ethics secured investment from Dechra Pharmaceuticals PLC (Dechra) in exchange for a 33% shareholding in the Group. A separate global license agreement (excluding Australia and NZ) was entered into by Dechra and Animal Ethics to secure the marketing and distribution rights of the Group’s proprietary platform technology in animals.

About Tri-Solfen
Tri-Solfen® is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts to immediately numb the wound with long lasting analgesic effect. It also acts as a barrier to environmental stimuli, promotes haemostasis and improves wound healing. Tri-Solfen® contains two proven topical local anaesthetics; fast-acting Lignocaine for immediate pain relief and long-acting Bupivacaine for prolonged post-operative pain relief. Adrenaline is included for its ability to reduce the shock and stress of blood loss, whilst prolonging the anaesthetic action. Tri-Solfen® also contains Cetrimide; an antiseptic widely used to cleanse skin and wounds and provides protection from bacterial contamination.

The global market potential for Tri-Solfen® is estimated to be in excess of AUD $350 million per year for the treatment of routine on farm procedures in calves, lambs and piglets.

Further information

Medical Ethics:

Allan Giffard, Managing Director
Charles Olsson, Marketing Director
+61 419 362 286

FTI Consulting:

Brett Pollard, Victoria Foster Mitchell
+44 (0)20 3727 1000

Testimonials

Patent Portfolio